Abstract
Technological breakthroughs in nucleic acid synthesis, gene cloning restriction enzyme analysis, and monoclonal antibody production will lead to significant improvements in molecular toxicology methods for testing and population monitoring. These improvements reside primarily in the specificity and quantitation of detection of toxicologically relevant DNA alterations and in the improved ability to measure those alterations in Vivo.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Olson, S.: Biotechnology, An Industry Comes of Age, National Academy Press, Washington, D. C., 1986.
Office of Science and Technology Policy. Proposal for a coordinated framework for regulation of biotechnology. Fed. Reg. 49: 50856–50907, 1984.
Waffe, S. O., and Lasagna, L.: From DNA to NDA—The impact of recombinant DNA technology on new drug development. Regul. Toxicol. Pharmacol. 5: 212–224, 1985.
Reedijk, J., and Lohman, P. H. M.: Cis-platinum; synthesis, antitumor activity and mechanisms of action. Pharm. Weekbl. (Sci.) 7 (5): 173–180, 1985.
Strudenski, A. B., Conner, B. J., Impraim, C. C., Teplitz, R. L., and Wallace, R. B.: Discrimination among the human ß^, ßs, ßC-globin genes using allele-specific oligonucleotide hybridization probes. Am. J. Hum. Genet. 37: 42–51, 1985.
Mekler, P. H., Delehanty, J. T., Lohman, P. H. M., Brouwer, J., Putte, P. v. D., Pearson, P., Pomwels, P. H., and Ramel, C.: The use of DNA technology to study gene alterations and gene evolution. Mutat. Res. 153: 13–55, 1985.
Maron, D. M., and Ames, B. N.: Revised methods for the Salmonella mutagenicity test. Mutat. Res. 113: 73–215, 1983.
Tindall, K. R., Stankowski, Jr., L. F., Machanoff, R., and Hsie, A. W.: Detection of deletion mutations in pSV2gpt-transformed cells. Mol. Cell. Biol. 4 (7): 1411–1415, 1984.
Barton, K. A., and Brill, W. J.: Prospects in plant genetic engineering. In Biotechnology and Biological Frontiers (P. H. Abelson, ed.), American Association for the Advancement of Science, Washington, D. C., pp. 121–131, 1984.
Baan, R. A., Lansbergen, M. J., deBruin, P. A. F., Willems, M. I., and Lohman, P. H. M.: The organ-specific induction of DNA adducts in 2-acetylaminofluorene-treated rats, studied by means of a sensitive immunochemical method. Mutat. Res. 150: 23–32, 1985.
McCormick, D.: Human gene therapy: The first round. Biotechnology 3: 689–693, 1985.
Palmiter, R. D., Brinster, R. L., Hammer, R. E., Trumbauer, M. E., Rosenfeld, M. G., Birnberg, N. C., and Evans, R. M.: Dramatic growth of mice that develop from eggs microinjected with metallothionein-growth hormone fusion genes, Nature 300: 61 1615, 1982.
Rawls, R.: Gene therapy. Chemical and Engineering News 62: 40, 1984.
Brusick, D. J.: Mutagenicity and carcinogenicity correlations between bacteria and rodents. In Cellular Systems for Toxicity Testing 407 (G. M. Williams, V. C. Dunkel, and V. A. Ray, eds.), New York Academy of Sciences, New York, pp. 164–176, 1983.
Brusick, D. J.: The role of short-term testing in carcinogen detection. Chemosphere 5: 403–417, 1978.
Shih, C., Shilo, B., Goldfarb, M. P., Dannenberg, A., and Weinberg, R. A.: Passage of phenotypes of chemically transformed cells via transfection of DNA and chromatin. Proc. Natl. Acad. Sci. USA 76: 5714–5718, 1979.
Weinberg, R. A.: Use of transfection to analyze genetic information and malignant transformation. Biochim. Biophys. Acta 651 (1): 25–35, 1981.
Bishop, J. M.: Cellular oncogenes and retroviruses. Annu. Rev. Biochem. 52: 301–354, 1983.
Evaluation of the Carcinogenic Risk of Chemicals to Humans. IARC October, 1982; suppl 4.
Garrett, N. E., Stock, H. F., Gross, M. R., and Waters, M. D.: An analysis of the spectra of genetic activity produced by known or suspected human carcinogens. Mutat. Res. 134: 89–111, 1984.
Aaronson, S. A., and Tronick, S. R.: Oncogenes. In Medical Genetics: 1984, Proceedings of symposium presented by the Foundation for Advanced Education in the Sciences, May 10–12, 1984, pp. 74–95.
Reddy, E. P., Reynolds, R. K., Santos, E., and Barbacid, M.: A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature 300: 145–152, 1982.
Varmus, H. E.: Mutations of cellular oncogenes as a basis for neoplastic change. In Mutation, Cancer and Malformation ( E. H. Y. Chu and W. M. Generoso, eds.), Plenum Press, New York, 1984, pp. 61–77.
Rowley, J. D.: Human oncogene locations and chromosome aberrations. Nature 301: 290–291, 1983.
Weisburger, J. H., and Williams, G. M.: The distinct health risk analyses required for genotoxic carcinogens and promoting agents. Environ. Health Perspect. 50: 233–245, 1983.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 1987 Springer Science+Business Media New York
About this chapter
Cite this chapter
Brusick, D. (1987). Applications from Biotechnology Research to Genetic Toxicology. In: Principles of Genetic Toxicology. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-1980-9_9
Download citation
DOI: https://doi.org/10.1007/978-1-4899-1980-9_9
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-1982-3
Online ISBN: 978-1-4899-1980-9
eBook Packages: Springer Book Archive